Tetraneuron works actively on two lines of research, both derived from the phosphorylation of E2F4 during the earliest stages of Alzheimer's disease.
Our first line of research seeks the effective blockade of such phosphorylation and consequent neural tetraploidization as an effective therapy against Alzheimer's disease.
Our second line of research studies the presence of phosphorylated E2F4 in the blood serum as an early biomarker of Alzheimer's disease.
The possibility of having an early diagnosis of Alzheimer's disease and an effective therapeutic method against this pathology, both developed by our company, envisions a hopeful future against this neurodegenerative pathology.
Tetraneuron is a private company founded in November 2012, which is developing a research project for the prevention of neuronal tetraploidy as a therapy for Alzheimer's disease.
The scientific team is led by Prof. José María Frade at the Cajal Institute, a reputed research institute belonging to the Higher Council for Scientific Research (CSIC), belonging to the Ministry of Science, Innovation and Universities of the Government of Spain.
Induction of cell death by endogenous nerve growth factor through its p75 receptor.
De José María Frade, Alfredo Rodriguez-Tébar & Yves-Alain Barde.
Nerve Growth Factor-Induced Cell Cycle Reentry in Newborn Neurons Is Triggered by p38MAPK-Dependent E2F4 Phosphorylation.
De Sandra M. Morillo, Erika P. Abanto, María J. Román & José M. Frade.
Somatic tetraploidy in specific chick retinal ganglion cells induced by nerve growth factor.
De Sandra M. Morillo, Pedro Escoll, Antonio de la Hera & José M. Frade
Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer’s-associated neuropathology.
De Noelia López-Sánchez a,b, Ángela Fontán-Lozano a, Anna Pallé a, Valentina González-Álvarez c, Alberto Rábano c, José L. Trejo a, José M. Frade
A mutant form of E2F4 prevents neuronal tetraploidization and cognitive deficits in 5xFAD mice without affecting Abeta deposition.
De López-Sánchez N y Frade JM (2017)
Scientific Board of Advisors
President of the Spanish Association of Scientific Entrepreneurs.
He has been Roche's scientific advisor in the field of DNA sequencing. For twelve years, from its foundation in 1998 to April 2009, it has been the promoter and founding partner of the company Sistemas Genómicos SL, where he held the position of Scientific and Strategic Director. He was founding partner and Scientific Director of the company Valentia BioPharma and the Institute of Genomic Medicine, both located in the Scientific Park of the University of Valencia. Among other projects, his collaboration with the multinational Life Technologies, in the development of applications of the ultrasecuenciación of genomes through the technology SOLiD stands out.
Among his published research articles, three publications are worthy of mention in the prestigious scientific journal Nature. At present, her research focuses on the development of genomic tools for the genetic diagnosis of hereditary diseases and in biopharmaceutical research to combat rare genetic diseases.